Nutraveris

Category 'INGREDIENTS'

Thursday, July 19, 2018
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

The objective of this double-blind, placebo-controlled study was to investigate if L. reuteri 6475 affects bone loss in older women with low BMD.

Women 75 to 80 years old with low BMD received 10(10) colony-forming units of L. reuteri 6475 daily or placebo for 12 months.

 

bone loss

 

L.reuteri 6475 reduced loss of total vBMD compared to placebo both in the intention-to-treat (ITT) analysis (-0.83% [95% confidence interval [CI], -1.47 to -0.19%] vs. -1.85% [95% CI, -2.64 to -1.07%]; mean difference 1.02% [95% CI, 0.02 to 2.03]) and per protocol analysis (-0.93% [95% CI, -1.45 to -0.40] vs. -1.86% [95% CI, -2.35 to -1.36]; mean difference 0.93% [95% CI, 0.21 to 1.65]. Adverse events did not differ between groups.

 

Authors concluded supplementation with L. reuteri 6475 should be further explored as a novel approach to prevent age-associated bone loss and osteoporosis.

 

 

Nilsson AG, Sundh D, Bäckhed F, Lorentzon M. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density – a randomized, placebo-controlled, double-blind, clinical trial. J Intern Med. 2018 Jun 21.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, July 17, 2018
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This systematic review and meta-analysis focused on the interest of chocolate milk on post-exercise recovery markers.

12 studies have been included in the analysis.

chocolate milk

Results showed that chocolate milk had no effect on time to exhaustion, ratings of perceived exertion, heart rate, serum lactate and creatine kinase.

However, in subgroups analysis, chocolate milk increases time to exhaustion in comparison to placebo (Mean difference: 0.78 min, 95% CI: 0.27-1.29, p = 0.003), but also in comparison to carbohydrate, protein and fat-containing beverages (MD: 6.13 min, 95% CI: 0.11-12.15, p = 0.006).

Moreover, in comparison to placebo, chocolate milk attenuated the exercise-induced increase in serum lactate (MD: -1.2 mmol/L, 95% CI: -2.06, -0.34, p = 0.006).

 

Therefore, chocolate milk may improve some markers of recovery from exercise.

 

 

Amiri M, Ghiasvand R, Kaviani M, Forbes SC, Salehi-Abargouei A. Chocolate milk for recovery from exercise: a systematic review and meta-analysis of controlled clinical trials. Eur J Clin Nutr. 2018 Jun 19.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, July 12, 2018
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

Melatonin is mainly used for the management sleep disorders, but some clinical trials have highlighted potential anti-inflammatory effects. To clarify this hypothesis, the authors of this meta-analysis have compiled 6 trials conducted in patients with metabolic syndrome and related disorders.

Melatonin

Results showed that melatonin supplementation significantly reduce C-reactive protein (standardized mean difference = -1.80, 95% CI: -3.27 to -0.32, p = 0.01, I²: 95.2) and IL-6 concentrations (SMD = -2.02, 95% CI: -3.57 to -0.47, p = 0.01, I²: 91.2).

In addition, melatonin tended to reduce TNF-α concentrations (SMD = -1.87, 95% CI: -3.81 to 0.07, p = 0.05, I²: 94.4).

 

Therefore, melatonin may reduce inflammation in patients with metabolic syndrome and related disorders.

 

 

Akbari M, Ostadmohammadi V, Tabrizi R, Lankarani KB, Heydari ST, Amirani E, Reiter RJ, Asemi Z. The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology. 2018 Jun 15.

 

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, July 10, 2018
Category : News, INGREDIENTS, INNOVATION | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This randomized and controlled trial examined the effects of a symbiotic yoghurt in patients with nonalcoholic fatty liver disease (NAFLD). 102 patients have been enrolled and divided in three groups: control (no supplement), standard yoghurt or symbiotic yoghurt.

The symbiotic yoghurt contained 10(8) CFU/mL of Bifidobacterium animalis and 1.5 g of inulin. Patients consumed 300 g of yoghurt per day for 24 weeks.

yoghurt

In comparison to the two other groups, the symbiotic yoghurt reduced the grade of NAFLD, as the levels of alanine aminotransferase (p = 0.008), aspartate aminotransferase (p < 0.001), alkaline phosphatase (p = 0.024) and γ-glutamyltransferase (p < 0.001).

Based on the results, it seems that the combination of inulin and B. animalis can significantly improve liver health in patients with NAFLD.

 

 

Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. J Nutr. 2018 Jun 20.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, July 5, 2018
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

Açai berries are rich in various polyphenols, which may have anti-diabetic properties. The purpose of this randomized and placebo-controlled study was to determine the effects of an açai beverage in patients with metabolic syndrome. 37 subjects received a control beverage or an acai beverage 325 mL twice daily, providing 1136 mg/L gallic acid equivalent) for 12 weeks.

Açai

Only two markers have been significantly affected by the açai consumption: the plasma level of IFN-γ (p = 0.0141) and the urinary level of 8-isoprostane (p = 0.0099). Parameters related to lipid and glucose metabolism remained unaffected by the supplementation.

 

Therefore, despite its recognition as “super-fruit”, açai may only provide few benefits for peole with metabolic syndrome.

 

 

Kim H, Simbo SY, Fang C, McAlister L, Roque A, Banerjee N, Talcott ST, Zhao H, Kreider RB, Mertens-Talcott SU. Açaí (Euterpe oleracea Mart.) beverage consumption improves biomarkers for inflammation but not glucose- or lipid-metabolism in individuals with metabolic syndrome in a randomized, double-blinded, placebo-controlled clinical trial. Food Funct. 2018 May 31.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87